Brenzavvy

Brenzavvy is an SGLT2 inhibitor that helps lower your average blood sugar level over 90 to 120 days. It’s FDA-approved to be used alongside diet and exercise to manage blood sugar in adults with type 2 diabetes.

Molecule Details :

  • Molecule Name :

    Bexagliflozin
  • Innovator :

    THERACOSBIO LLC
  • Approval Date :

    20-Jan-23
  • NCE-1 Date :

    20-Jan-27
  • NCE Date :

    20-Jan-28
  • Dosage Form :

    Tablet
  • Strength :

    20mg
  • Therapeutic Category :

    Antidiabetic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    663
  • 2026 :

    764
  • 2027 :

    845
  • 2028 :

    928
  • 2029 :

    1,015
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?